Replies to post #2760 on Radient Pharmaceuticals Corporation fka RXPC

[Gold Seeker]

Future doc, what is your source for this statement? "They have a few foreign factories that can be added onto in order to meet a large demand."


If you are thinking Jade, let me tell you more about Jade.

The Chinese drug and testing industry is highly regulated, maybe even more than the USA. Their agency is the SFDA. They don't mess around over there. In 2007, the executed the head of the SFDA for alledged corruption.

In 2004, AMDL, the previous name for the company, began extensive trials for DR70 (Onko Sure). In 2006, the applied for medical device approval from the SFDA. Also not long after, they negotialted a deal to purchase Jade in exchange for shares in RPC. There was no cash involved because the company has never had any significant amount of cash and the owners of Jade anticipated the revenue from sales of Onko Sure in China would make them millions.

Relations were fine with Jade until 2009. In early 2009, the SFDA REJECTED Onko Sure for approval. BOOM. Jade management exploded. Now they had sold the company for worthless stock who had no product to sell in China.

Question: Why would the SFDA reject a test that was FDA cleared in the USA?

In the same CC where RPC management agreed that Onko Sure had 10 false positives for every accurate results, they also gave a timeline required for any additonal attempt to obtain approval in China. It was years and no additonal attempts have been made.

[Gold Seeker]

Future doc stated: "I personally think that if the Mayo results are what RPC is indicating them to be, then they could receive a barrage of orders that could turn this into a completely legitimate business, financially speaking."

The big question is the sensitivity and specificity of the new version under trials?

Ask your self a few questions.

Has the company been candid with investors? In Mid February 2010, the company stated they were on track to sell 1200 test kits. The quarter was half over at the time but when the first quarter sales were reported, only about 200 test kits were sold. Was that truth in advertising?

The number one goal of management is to sell ivestors stock. If they do not, the company goes bankrupt and POOF, their goes the CEO's more than half million income.

Future doc, you are trusting the company to have a much better test in trials. Do you understand that the company could just begin selling that test in India instead of the old one? There is no approval process in India. When the question was asked about all the false positives the test had, why didn't they just say, "oh, the new version doesn't have all those false positives"? Instead, they said you need to pre-screen to eliminate some of those false positives.

If you think the company is going to give you an honest assessment of the new test, see the first paragraph above.

Do I think the new version will be better? No I do not. The same reasons for FDP to have all the false indications are still there.

Management has already done inhouse studies on the new version. They also understand that in house studies are also not relied upon by doctors. If that version cured the problems with the test, management would be screaming it to the high heavens right now.